Cardinal Health (CAH)

Cardinal Health is one of the largest healthcare companies in North America, occupying a critical position in the pharmaceutical and medical supply chain. The company operates as a distributor and service provider, connecting drug manufacturers and medical suppliers with hospitals, retail pharmacies, clinics, and individual patients. Its business model centers on scale, efficiency, and the recurring nature of healthcare demand—hospitals and pharmacies cannot operate without steady supplies of medications and equipment.

The core business: distribution and logistics

Cardinal Health’s primary revenue comes from distributing pharmaceuticals and medical/surgical supplies. The company buys in bulk from manufacturers, operates an extensive network of warehouses and distribution centers, and delivers to healthcare providers with speed and reliability. This intermediary role is essential but competitive; Cardinal competes partly on service (next-day delivery, just-in-time inventory), partly on price, and partly on offering value-added services like purchasing analytics, inventory management software, and clinical information.

Alongside distribution, Cardinal provides specialty pharmaceutical services—handling complex, high-cost medications (oncology drugs, biologics, immunosuppressants) that require cold-chain logistics, patient counseling, and close coordination with prescribers. It also operates patient care services, including at-home infusion, medication therapy management, and disease monitoring, which tie the company deeper into patient outcomes and create stickier, higher-margin relationships.

A long history of consolidation

Cardinal Health was founded in 1971 as a drug wholesaler in Ohio; the name itself signals its role as a “cardinal” or central hub in the supply chain. Over decades, it grew through acquisitions, absorbing competitors and specialists. Major deals included the purchase of Allegra and Medisgroup to expand pharmaceutical distribution, and more recently the acquisition of specialty pharmacy and provider service businesses. This acquisition-driven strategy is typical among healthcare middlemen: consolidation yields scale, negotiating power with manufacturers, and platform for adding services. However, it also adds complexity—the company must integrate systems, cultures, and operations while maintaining uninterrupted service to hospitals and pharmacies.

How it makes money: three revenue streams

Cardinal generates revenue from distributing pharmaceutical products to retail and institutional customers, supplying medical/surgical products and equipment, and providing specialty pharmaceutical and patient care services. Pharmaceutical distribution is the largest segment by volume but operates on thin margins (often 2-3% gross margin), so success depends on enormous scale, operational efficiency, and negotiating leverage. The medical products business is somewhat less price-sensitive. Specialty services carry higher margins and growing importance as healthcare shifts toward integrated, outcomes-focused care.

A large and growing portion of revenue comes from generic drugs; these are lower-margin than brand-name drugs but represent steady, recurring demand. Cardinal also earns revenue from patient assistance programs (helping uninsured or underinsured patients access medications) and from data and analytics services that help customers optimize procurement.

Key characteristics and pressures

Cardinal operates in a duopoly-like distribution market alongside McKesson and Amerisource Bergen, with a few smaller players. This consolidated structure gives the big three substantial leverage with manufacturers but also makes them targets for pricing pressure—manufacturers want better terms, and healthcare systems demand lower costs. The opioid epidemic of the 2000s and 2010s cast a shadow over Cardinal’s reputation: the company faced lawsuits (settled for multibillion-dollar payments) over its role in distributing opioids without adequate monitoring or safeguards. These settlements materially impacted earnings and remain a reputational risk.

The healthcare distribution market is also subject to regulatory scrutiny, drug price regulation debates, and consolidation pressure. Government programs (Medicare, Medicaid) are the largest payers for many medications, and they negotiate drug prices heavily. Pharmacy benefit managers (PBMs), which sit between insurers and pharmacies, also exert significant pricing power. Cardinal must navigate relationships with all of these players while maintaining margins.

Specialty pharmacy is higher-growth and higher-margin but concentrated in fewer, sicker patients and subject to different regulatory and reimbursement dynamics. Competition from direct-to-patient models (Amazon Pharmacy, digital health platforms) is also increasing, though distribution scale and clinical depth remain hard to replicate.

Key metrics and what to watch

On regulatory filings (10-K), track pharmaceutical distribution volumes and pricing trends (GAAP revenue growth vs. price/volume mix), gross margins by segment, and cash flow from operations. Generic drug penetration and specialty pharmacy growth rates reveal structural shifts. Watch also for changes in relationship with major customers (hospital chains, large pharmacy chains) and any contract wins or losses.

Cardinal’s stock performance reflects both the stability of healthcare logistics (recurring, essential revenue) and vulnerability to healthcare reform, PBM consolidation, and pricing pressure. The company trades at a moderate valuation given steady cash generation but tempered growth and regulatory/legal risks. Debt levels matter because the company has used leverage to fund acquisitions; monitor debt-to-EBITDA and interest coverage. Cash dividends and share repurchases are important to total shareholder return, funded from operating cash flow.

Key financial metrics to monitor: revenue growth (slow, often mid-single-digit), gross margin (trending down due to pricing pressure), operating margin, free cash flow conversion, and return on invested capital. The business generates steady cash but growth is limited without M&A or market share gains. A recession affects volume (fewer procedures, less medication use) but Cardinal’s position in the supply chain provides some insulation; people still take essential medications even in downturns.

Cardinal Health is a classic “middle operator” in a crucial but fragmented industry. Its scale is a fortress, but margins are perpetually under siege. Success hinges on operational excellence, customer retention, and skillful navigation of regulatory and pricing pressures.